Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for VitaNova Life Sciences's Cyclically Adjusted PB Ratio or its related term are showing as below:
VNOV'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 34.5 Med: 34.5 Max: 37.97
Current: 37.97
During the past 10 years, VitaNova Life Sciences's highest Cyclically Adjusted PB Ratio was 37.97. The lowest was 34.50. And the median was 34.50.
VNOV's Cyclically Adjusted PB Ratio is not ranked
in the Medical Distribution industry.
Industry Median: 1.14
vs VNOV: 37.97
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
VitaNova Life Sciences's adjusted book value per share data of for the fiscal year that ended in Apr26 was $0.246. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.04 for the trailing ten years ended in Apr26.
Shiller PE for Stocks: The True Measure of Stock Valuation
VitaNova Life Sciences (OTCPK:VNOV) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
VitaNova Life Sciences Cyclically Adjusted PB Ratio Related Terms
VitaNova Life Sciences Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for VitaNova Life Sciences's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VitaNova Life Sciences Cyclically Adjusted PB Ratio Chart
VNOV vs HKPD, COSM, SNYR: Cyclically Adjusted PB Ratio Comparison
For the Medical Distribution subindustry, VitaNova Life Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VitaNova Life Sciences Cyclically Adjusted PB Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, VitaNova Life Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where VitaNova Life Sciences's Cyclically Adjusted PB Ratio falls into.
VitaNova Life Sciences Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 34.50 mean?
VitaNova Life Sciences (VNOV) has a Cyclically Adjusted PB Ratio of 34.50 as of Aug. 01, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on VitaNova Life Sciences and its competitors. This is near median its historical median of 34.50. Over the past decade, VitaNova Life Sciences' Cyclically Adjusted PB Ratio has ranged from 34.50 to 37.97.
Is VitaNova Life Sciences' Cyclically Adjusted PB Ratio too high?
VitaNova Life Sciences' current Cyclically Adjusted PB Ratio of 34.50 is near median its 10-year median of 34.50. Over the past 10 years, this metric has ranged from a low of 34.50 to a high of 37.97. The Medical Distribution industry median Cyclically Adjusted PB Ratio is 1.14. VitaNova Life Sciences' value of 34.50 is 2926.3% above this industry median. Overall, VitaNova Life Sciences has a GF Scoreâ„¢ of 51/100, reflecting its overall financial health beyond just this single metric.
How does VitaNova Life Sciences' Cyclically Adjusted PB Ratio compare to HKPD and COSM?
VitaNova Life Sciences' Cyclically Adjusted PB Ratio of 34.50 can be compared against companies in the Medical Distribution industry. The industry median Cyclically Adjusted PB Ratio is 1.14. VitaNova Life Sciences' value of 34.50 is 2926.3% above this benchmark. Historically, VitaNova Life Sciences' own Cyclically Adjusted PB Ratio has ranged from 34.50 to 37.97 over the past decade. While the company's 10-year median is 34.50 vs. the industry median of 1.14, VitaNova Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Medical Distribution company?
The median Cyclically Adjusted PB Ratio among Medical Distribution companies is 1.14, based on 92 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VitaNova Life Sciences's current Cyclically Adjusted PB Ratio of 34.50 is 2926.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on VitaNova Life Sciences and its competitors. For the Medical Distribution industry, the median Cyclically Adjusted PB Ratio is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VitaNova Life Sciences's current Cyclically Adjusted PB Ratio is 34.50, which is near median its own 10-year median of 34.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VitaNova Life Sciences stock overvalued right now?
VitaNova Life Sciences (VNOV) has a current Cyclically Adjusted PB Ratio of 34.50. The stock's GF Value™ is $5.95, compared to a current price of $1.38 — trading 76.8% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 34.50, which is near median its 10-year median of 34.50 and 2926.3% above the Medical Distribution industry median of 1.14. VitaNova Life Sciences' overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For VitaNova Life Sciences (VNOV), the current Cyclically Adjusted PB Ratio is 34.50 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VitaNova Life Sciences (VNOV) Overvalued in 2026?
Based on GuruFocus' analysis, VitaNova Life Sciences stock appears to be undervalued.
The current stock price of $1.38 is trading 76.8% below its estimated GF Value™ of $5.95.
Key valuation signals for VNOV:
Cyclically Adjusted PB Ratio: 34.50 (near median its 10-year median of 34.50)
GF Value™: $5.95 vs. price of $1.38 (76.8% below fair value)
Industry Position: 2926.3% above the Medical Distribution median
No single metric tells the full story. See the VNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VitaNova Life Sciences Corp, formerly Yijia Group Corp provides business consulting services to domestic and international customers. The Company provides consulting services to its clients with regards to funding and other financial matters.The company's operating segments are The consulting services Segment mainly provides consulting advisory services in management, business, accounting and finance; and the Healthcare Segment mainly provides healthcare products and health consultation services to customers. The sale and distribution of healthcare products, such as Nicotinamide Riboside capsules, has only one performance obligation under the fixed-fee arrangements. and the majority of its revenue generates from Sales of healthcare products.
51GF Score
Get the complete analysis for VNOV
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VNOV has been successfully added to your 
